C3i is attending the 10th Canadian Cancer Immunotherapy Consortium this week!
C3i will attend the 10th Canadian Cancer Immunotherapy Consortium in Montreal from December 13th to 15th to engage with researchers, clinicians and industry leaders in the Cancer Immunotherapy field. Danielle de Verteuil, for the Biomarker & Diagnostics unit, and Arnaud Deladeriere for the cGMP Manufacturing unit, will be representing and promoting C3i for its outstanding capacity to help biotech companies and pharmas to achieve their objectives.
C3i was on the ground at ISSCR 2026 in Montréal, where one message came through clearly: cell and gene therapy is moving from scientific promise to clinical and commercial reality. Academia and industry have taken meaningful steps forward this past year, and the momentum is building. A few takeaways stood out: Clinical progress is accelerating […]
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
